Middle East & Africa Women’s Health Market Size & Outlook

The women’s health market in Middle East & Africa is expected to reach a projected revenue of US$ 1,918.7 million by 2030. A compound annual growth rate of 5.8% is expected of Middle East & Africa women’s health market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,290.6
Forecast, 2030 (US$M)
$1,918.7
CAGR, 2024 - 2030
5.8%
Report Coverage
Middle East & Africa

MEA women’s health market highlights

  • The MEA women’s health market generated a revenue of USD 1,290.6 million in 2023.
  • The market is expected to grow at a CAGR of 5.8% from 2024 to 2030.
  • In terms of segment, contraceptives was the largest revenue generating application in 2023.
  • Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
  • Country-wise, South Africa is expected to register the highest CAGR from 2024 to 2030.


MEA data book summary

Market revenue in 2023USD 1,290.6 million
Market revenue in 2030USD 1,918.7 million
Growth rate5.8% (CAGR from 2023 to 2030)
Largest segmentContraceptives
Fastest growing segmentEndometriosis & Uterine Fibroids
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationHormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS)
Key market players worldwideAbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring


Other key industry trends

  • In terms of revenue, MEA region accounted for 2.9% of the global women’s health market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 17,433.6 million by 2030.

Contraceptives was the largest segment with a revenue share of 36.66% in 2023. Horizon Databook has segmented the Middle East & Africa women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.


The growing prevalence of infertility and other gynecological disorders are some of the crucial factors responsible for boosting market growth. Population growth in the region and the high prevalence of female infertility indicate the growing adoption of women’s health products.

The adoption of modern contraceptives is comparatively lower than traditional ones in the MEA. However, several governments in this region are actively undertaking initiatives to promote the use of modern contraceptives.

These factors are expected to drive the women’s health market in the coming years. However, limited resources, fragmented healthcare systems, and financial restraints in several MEA countries are likely to hamper the market growth over the forecast period.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Women’s Health Market Companies

Name Profile # Employees HQ Website

MEA women’s health market size, by country, 2018-2030 (US$M)

Middle East & Africa Women’s Health Market Outlook Share, 2023 & 2030 (US$M)

MEA women’s health market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more